ClinicalTrials.gg

TargetBeta

CDH17

cadherin 17 · also HPT-1, cadherin · 7D cadherins

7 programs in company-led studies act on CDH17, from 7 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
AMT-676ruleMultitude Therapeuticsphase 222 running–the studies' text
Anti-CDH17 Antibody-drug Conjugate HS-20110Hansoh Pharmaceutical Groupphase 222 running–the company's pipeline
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911ruleMabwell (Shanghai) Biosciencephase 222 running–NCIt
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruleDualityBiophase 211 running–NCIt
LM-350Sino Biopharmaceuticalphase 211 running–the company's pipeline
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 111 running–NCIt
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217ruleArriVent BioPharmaphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.